GrayMatters Health | Digital biomarkers for mental health care

Transforming innovation into accessible mental health treatment help change lives. GrayMatters Health leading transformation empowering mental healthcare professionals with technology that augments therapies help improve patient outcomes patient lives. This innovation based world’ first digital biomarker brain activity associated with mental health disorders. Prism PTSD first device receive clearance prescribed adjunct treatment stress disorder (PTSD). Prism uses biomarker help patients learn regulate brain activity associated with PTSD symptoms, adjunctive treatment symptoms associated with PTSD, used under direction healthcare professional. Prism’ biomarker technology been extensively researched. clinical trials, 67% patients overall showed clinically significant symptom improvement  three months after completing treatment. Installation training morning treat patients that same afternoon. operated . Mild side effects, such headache fatigue   post treatment.  Prism does patients trauma  studies have shown 10% attrition. “ encouraged that Prism, adjunctive therapy, will significantly benefit patients with PTSD allow clinics offer more options better outcomes.” Professor Charlie Marmar, Principal Investigator Langone Disclaimer: information this website intended substitute professional medical advice. Always discuss treatment options treatment outcomes with your physician other qualified mental health…